A leader in breast cancer diagnostics, Roche Diagnostics offers numerous cancer diagnostic assays that enable pathology labs to deliver accurate results with confidence. We provide a robust menu of breast cancer diagnostic tools. Our portfolio of products delivers the high sensitivity and specificity you need from your assays.
Immunohistochemistry (IHC) analysis and in situ hybridisation (ISH) analysis
In England, breast cancer represented 15.1% of the total number of cancers diagnosed in 20171. In developed countries breast cancer-related mortality has declined, in part due to therapeutic advances and evolution of biomarkers. For example, Immunohistochemistry (IHC) analysis and in situ hybridisation (ISH) analysis provide important information related to tumour biology, help profile types of breast cancer and may improve treatment decisions.
Clinical benefit
The VENTANA breast cancer diagnostic assays could be used to aid in diagnosing patients with breast cancer at various stages. This could assist the clinician with either early detection or personalised treatment options.
Analytical advantage
Specific and sensitive rabbit monoclonal antibodies, best-in-class probes and powerful detection systems help you diagnose precisely and confidently.
Testing efficiency
Our comprehensive breast cancer workflow solution delivers fully-automated assays, with digital pathology and workflow solutions that free resources, reduce labour costs and time to results.